Pharmacokinetics of ertapenem in a three-weekly dosing regime in patients with end stage renal disease depending on hemodialysis

Phase 4

Completed

• Conditions: End stage renal disease; hemodialysis; infection; 10004018; 10038430

• Registration Number: NL-OMON34802
• Lead Sponsor: Sint Franciscus Gasthuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 8

Inclusion Criteria

- Hemodialysis patient

Exclusion Criteria

- Age < 18
- Liverdisease
- Alcoholabuse
- Allergy for carbapenems
- Diarrhoea
- Use of valproicacid, probenicid
- Pregnancy or lactation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>A pharmacokinetic model which describes the plasma concentration time curves<br /><br>for Ertapenem.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Clinical improvement of the infection</p><br>